Zacks Investment Research upgraded shares of Neos Therapeutics, Inc. (NASDAQ:NEOS) from a hold rating to a strong-buy rating in a research report sent to investors on Wednesday. The brokerage currently has $8.00 price objective on the stock.

According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “

A number of other equities analysts also recently commented on the stock. ValuEngine downgraded shares of Neos Therapeutics from a sell rating to a strong sell rating in a research note on Saturday, May 27th. BMO Capital Markets reaffirmed an outperform rating and set a $15.00 target price on shares of Neos Therapeutics in a research note on Tuesday, June 20th. Cantor Fitzgerald started coverage on shares of Neos Therapeutics in a research note on Monday, July 31st. They set an overweight rating and a $20.00 target price on the stock. Finally, Royal Bank Of Canada set a $12.00 target price on shares of Neos Therapeutics and gave the stock an outperform rating in a research note on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $13.83.

Neos Therapeutics (NASDAQ NEOS) opened at 7.05 on Wednesday. The company has a 50-day moving average price of $6.88 and a 200-day moving average price of $7.04. The company’s market cap is $197.96 million. Neos Therapeutics has a 1-year low of $4.85 and a 1-year high of $9.60.

Neos Therapeutics (NASDAQ:NEOS) last issued its earnings results on Tuesday, August 8th. The company reported ($0.83) EPS for the quarter, hitting analysts’ consensus estimates of ($0.83). Neos Therapeutics had a negative net margin of 511.74% and a negative return on equity of 611.78%. The company had revenue of $4.91 million for the quarter. On average, analysts expect that Neos Therapeutics will post ($3.22) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Neos Therapeutics, Inc. (NEOS) Upgraded by Zacks Investment Research to “Strong-Buy”” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/24/neos-therapeutics-inc-neos-upgraded-by-zacks-investment-research-to-strong-buy.html.

Several large investors have recently made changes to their positions in the stock. State of Wisconsin Investment Board bought a new stake in shares of Neos Therapeutics during the second quarter worth $102,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Neos Therapeutics during the second quarter worth $110,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Neos Therapeutics during the second quarter worth $118,000. Mission Wealth Management LLC acquired a new position in shares of Neos Therapeutics during the first quarter worth $122,000. Finally, Tudor Investment Corp ET AL acquired a new position in shares of Neos Therapeutics during the second quarter worth $146,000. Institutional investors and hedge funds own 35.38% of the company’s stock.

About Neos Therapeutics

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Receive News & Stock Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related stocks with our FREE daily email newsletter.